NCT01514500View on ClinicalTrials.gov

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

January 16, 2012

Primary Completion Date

March 18, 2013

Study Completion Date

March 18, 2013

Conditions
Growth Hormone DisorderAdult Growth Hormone DeficiencyGrowth Hormone Deficiency in ChildrenHealthy
Interventions
DRUG

somapacitan

Administered s.c. (subcutaneously, under the skin)

DRUG

placebo (somapacitan)

Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY